Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Oncosec Medical (ONCS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 85,854
  • Shares Outstanding, K 52,350
  • Annual Sales, $ 0 K
  • Annual Income, $ -21,450 K
  • 36-Month Beta 3.02
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.49

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 07/31/18
See More
  • Average Estimate -0.18
  • Number of Estimates 2
  • High Estimate -0.18
  • Low Estimate -0.18
  • Prior Year -0.28
  • Growth Rate Est. (year over year) +35.71%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.33 +23.31%
on 09/20/18
1.74 -5.75%
on 10/05/18
+0.32 (+24.24%)
since 09/18/18
3-Month
1.17 +40.17%
on 08/03/18
1.74 -5.75%
on 10/05/18
+0.34 (+26.15%)
since 07/18/18
52-Week
1.04 +57.69%
on 10/26/17
2.95 -44.41%
on 11/13/17
+0.36 (+28.13%)
since 10/18/17

Most Recent Stories

More News
OncoSec Initiates KEYNOTE-890, a Phase 2 Clinical Trial of TAVO in Combination with Merck's KEYTRUDA® (pembrolizumab) for the Treatment of Late-Stage Triple Negative Breast Cancer

OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS), a company developing intratumoral cancer immunotherapies, today announced that it has initiated KEYNOTE-890, a Phase 2 clinical trial for the treatment...

ONCS : 1.64 (+3.80%)
OncoSec Announces Closing of First Tranche of $15 Million At Market Investment from Alpha Holdings, Inc.

OncoSec Medical Incorporated (OncoSec) (NASDAQ: ONCS), a company developing intratumoral cancer immunotherapies, today announced the closing of the first $8 million tranche of its $15 million investment...

ONCS : 1.64 (+3.80%)
OncoSec Chief Scientific Officer to Present at Advances in Immuno-Oncology USA Congress

OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS), a company developing intratumoral cancer immunotherapies, today announced that its Chief Scientific Officer Christopher G. Twitty, PhD, will give a...

ONCS : 1.64 (+3.80%)
Data from OncoSec's OMS-100 Clinical Trial Accepted for Oral Presentation at the 2018 Melanoma Bridge Conference

OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS), a company developing intratumoral cancer immunotherapies, today announced that Dr. Alain Algazi, Associate Professor of Medicine at UCSF, will present...

ONCS : 1.64 (+3.80%)
OncoSec to Present at Cantor Fitzgerald Global Healthcare Conference

OncoSec Medical Incorporated (OncoSec) (NASDAQ: ONCS), a company developing intratumoral cancer immunotherapies, today announced that Daniel J. O'Connor, President and Chief Executive Officer of OncoSec,...

ONCS : 1.64 (+3.80%)
OncoSec Announces $15 Million At Market Investment from Alpha Holdings, Inc.

OncoSec Medical Incorporated (OncoSec) (NASDAQ: ONCS), a company developing intratumoral cancer immunotherapies, today announced that it has secured a $15 million investment from Alpha Holdings, Inc. (KOSDAQ:...

ONCS : 1.64 (+3.80%)
OncoSec Appoints Alain Algazi, MD, as Clinical Strategic Advisor

OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS), a company developing intratumoral cancer immunotherapies, today announced an enhancement to the company's medical and clinical leadership with the...

ONCS : 1.64 (+3.80%)
New Research: Key Drivers of Growth for OncoSec Medical, AcelRx Pharmaceuticals, Cameco, Prestige Brand, Berry Global Group, and A-Mark Precious Metals -- Factors of Influence, Major Initiatives and Sustained Production

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of OncoSec Medical Incorporated...

BERY : 42.89 (-3.03%)
ACRX : 4.15 (-0.72%)
PBH : 37.92 (-2.32%)
ONCS : 1.64 (+3.80%)
CCJ : 11.56 (-2.36%)
AMRK : 13.53 (-2.59%)
Arch Therapeutics Appoints Healthcare Industry Executive Punit Dhillon to Board of Directors

Arch Therapeutics, Inc. (OTCQB:ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device(TM) ("AC5(TM)"), today announced the appointment of Punit Dhillon, former President & CEO...

NMUS : 0.4750 (+10.47%)
ONCS : 1.64 (+3.80%)
EMH.VN : 4.430 (-2.85%)
ARTH : 0.4280 (+12.63%)
OncoSec Presents Update from Triple Negative Breast Cancer Program at 3rd Global Insight Conference on Breast Cancer

OncoSec Medical Incorporated (OncoSec) (NASDAQ: ONCS), a company developing intratumoral cancer immunotherapies, today announced that Sharron Gargosky, PhD, Chief Clinical and Regulatory Officer, presented...

ONCS : 1.64 (+3.80%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More Share

Trade ONCS with:

Business Summary

OncoSec Medical Incorporated is a biomedical company engaged in the designing, development and commercialization of therapeutic oncology products. It also develops novel OMS ElectroOncology therapies and OncoSec Medical System for the treatment of solid tumors. OncoSec Medical Incorporated is based in...

See More

Key Turning Points

2nd Resistance Point 1.79
1st Resistance Point 1.71
Last Price 1.64
1st Support Level 1.56
2nd Support Level 1.49

See More

52-Week High 2.95
Fibonacci 61.8% 2.22
Fibonacci 50% 2.00
Fibonacci 38.2% 1.77
Last Price 1.64
52-Week Low 1.04

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar